Additionally, Genomic Health, in partnership with investigators from several academic institutions, will present a separate study, "Recurrence risk of node-negative and ER-positive early stage breast cancer patients by combining Recurrence Score, pathologic, and clinical information: A meta analysis approach" (Abstract #509), demonstrating that combining the Oncotype DX Recurrence Score with pathology and clinical measures (RSPC) supplements the assessment of baseline recurrence risk. The Oncotype DX Recurrence Score (RS), and the individual biology it identifies, remains the recommended method for predicting relative chemotherapy benefit for early-stage breast cancer.
Physicians currently integrate the RS result with other pathology and clinical (PC) measures through their own individual processes and have not had a formal way of integrating this information when assessing recurrence risk. Using this meta-analysis approach, Genomic Health and its clinical collaborators have employed statistical methods to leverage the larger experience of over 1,700 breast cancer patients from two randomized trials, and integrate the RS with PC measures in order to provide greater clarity, especially when PC measures and the RS are discordant.
The RSPC prediction of recurrence risk, which is driven in large part by the RS, reflects the individualized assessment of the continuous biology of breast cancer. For the majority of patients, the prediction of recurrence risk by RSPC and RS are similar. As expected, changes in risk category occurred more frequently for scores near the category boundaries and were most likely for patients with intermediate Recurrence Scores. The integration of all these measures reduced the number of p
|SOURCE Genomic Health, Inc.|
Copyright©2010 PR Newswire.
All rights reserved